Trials / Withdrawn
WithdrawnNCT04985825
Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pega-One S.A.S. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the anti-tumor activity, safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of imgatuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) with enhanced antibody-dependent cellular cytotoxicity (ADCC) in patients with advanced cutaneous squamous cell carcinoma (CSCC). Quality of life of patients treated with imgatuzumab will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imgatuzumab | Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle. |
Timeline
- Start date
- 2021-12-16
- Primary completion
- 2022-08-17
- Completion
- 2022-08-17
- First posted
- 2021-08-02
- Last updated
- 2022-09-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04985825. Inclusion in this directory is not an endorsement.